BRPI1011624A2 - composição, métodos para reduzir um ou mais efeitos colaterais da terapia de glicocorticóide, e para tratar ou previnir um padrão de secreção de glicocorticóide endógeno diminuído ou interrompido em um paciente. - Google Patents
composição, métodos para reduzir um ou mais efeitos colaterais da terapia de glicocorticóide, e para tratar ou previnir um padrão de secreção de glicocorticóide endógeno diminuído ou interrompido em um paciente.Info
- Publication number
- BRPI1011624A2 BRPI1011624A2 BRPI1011624A BRPI1011624A BRPI1011624A2 BR PI1011624 A2 BRPI1011624 A2 BR PI1011624A2 BR PI1011624 A BRPI1011624 A BR PI1011624A BR PI1011624 A BRPI1011624 A BR PI1011624A BR PI1011624 A2 BRPI1011624 A2 BR PI1011624A2
- Authority
- BR
- Brazil
- Prior art keywords
- glucocorticoid
- decreased
- patient
- treating
- preventing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200900470 | 2009-04-07 | ||
PCT/EP2010/002178 WO2010115615A1 (en) | 2009-04-07 | 2010-04-07 | Improved glucocorticoid therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1011624A2 true BRPI1011624A2 (pt) | 2016-03-22 |
Family
ID=41042297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1011624A BRPI1011624A2 (pt) | 2009-04-07 | 2010-04-07 | composição, métodos para reduzir um ou mais efeitos colaterais da terapia de glicocorticóide, e para tratar ou previnir um padrão de secreção de glicocorticóide endógeno diminuído ou interrompido em um paciente. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20120183610A1 (pt) |
EP (1) | EP2416783B1 (pt) |
JP (1) | JP2012522816A (pt) |
CN (1) | CN102448464A (pt) |
AU (1) | AU2010234320A1 (pt) |
BR (1) | BRPI1011624A2 (pt) |
CA (1) | CA2757858C (pt) |
IL (1) | IL215481A (pt) |
MX (1) | MX2011010525A (pt) |
NZ (2) | NZ595428A (pt) |
SG (1) | SG174583A1 (pt) |
WO (1) | WO2010115615A1 (pt) |
ZA (1) | ZA201107297B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0401031D0 (sv) | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
BR112012029466A2 (pt) * | 2010-05-20 | 2017-03-01 | Duocort Phama Ab | "composição de glicocorticoide, método melhorado para tratar a deficiência de glicocorticoide, e, método para dar origem a uma dosagem individualizada de glicocorticoides" |
GB201119985D0 (en) | 2011-11-19 | 2012-01-04 | Diurnal Ltd | Treatment of adrenal insufficiency |
KR102317399B1 (ko) * | 2012-01-26 | 2021-10-26 | 반다 파마슈티칼즈, 인코퍼레이티드. | 일주기 리듬 장애의 치료 |
US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
GB201202433D0 (en) * | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
GB201308933D0 (en) | 2013-05-17 | 2013-07-03 | Diurnal Ltd | Paediatric composition |
CN105530867B (zh) | 2013-08-21 | 2018-11-13 | 传感技术股份有限公司 | 用于生物感测分析物的体内保护的药物洗脱 |
US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
CN107115308B (zh) * | 2016-02-23 | 2021-02-23 | 天津金耀集团有限公司 | 一种氢化可的松双相缓释片剂组合物 |
EP3873342A4 (en) | 2018-11-02 | 2022-08-10 | Senseonics, Incorporated | DRUG ELUTING MATRIX ON AN ANALYTICAL INDICATOR |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2260384C3 (de) * | 1972-12-09 | 1979-11-29 | Hoechst Ag, 6000 Frankfurt | Oral zu applizierendes Corticosteroid-Präparat |
DE19718012C1 (de) * | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
US6156743A (en) * | 1999-10-18 | 2000-12-05 | Whitcomb; John E. | Method of decreasing fatigue |
GB0119848D0 (en) * | 2001-08-15 | 2001-10-10 | Univ Sheffield | Delayed and sustained drug release |
GB0400031D0 (en) * | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
SE0401031D0 (sv) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
WO2005102287A2 (en) * | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
GB0623740D0 (en) * | 2006-11-28 | 2007-01-10 | Diurnal Ltd | Treatment of disease |
-
2010
- 2010-04-07 SG SG2011069911A patent/SG174583A1/en unknown
- 2010-04-07 NZ NZ595428A patent/NZ595428A/xx unknown
- 2010-04-07 BR BRPI1011624A patent/BRPI1011624A2/pt not_active Application Discontinuation
- 2010-04-07 US US13/263,718 patent/US20120183610A1/en not_active Abandoned
- 2010-04-07 EP EP10712907.4A patent/EP2416783B1/en active Active
- 2010-04-07 CA CA2757858A patent/CA2757858C/en active Active
- 2010-04-07 JP JP2012503920A patent/JP2012522816A/ja active Pending
- 2010-04-07 AU AU2010234320A patent/AU2010234320A1/en not_active Abandoned
- 2010-04-07 MX MX2011010525A patent/MX2011010525A/es unknown
- 2010-04-07 CN CN2010800161696A patent/CN102448464A/zh active Pending
- 2010-04-07 NZ NZ602010A patent/NZ602010A/xx unknown
- 2010-04-07 WO PCT/EP2010/002178 patent/WO2010115615A1/en active Application Filing
-
2011
- 2011-10-02 IL IL215481A patent/IL215481A/en active IP Right Grant
- 2011-10-05 ZA ZA2011/07297A patent/ZA201107297B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL215481A0 (en) | 2011-12-29 |
EP2416783B1 (en) | 2018-11-07 |
CA2757858A1 (en) | 2010-10-14 |
CN102448464A (zh) | 2012-05-09 |
US20120183610A1 (en) | 2012-07-19 |
AU2010234320A1 (en) | 2011-10-27 |
EP2416783A1 (en) | 2012-02-15 |
ZA201107297B (en) | 2012-06-27 |
SG174583A1 (en) | 2011-10-28 |
IL215481A (en) | 2017-11-30 |
NZ595428A (en) | 2013-04-26 |
CA2757858C (en) | 2017-03-28 |
JP2012522816A (ja) | 2012-09-27 |
NZ602010A (en) | 2013-11-29 |
MX2011010525A (es) | 2012-04-02 |
WO2010115615A1 (en) | 2010-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1011624A2 (pt) | composição, métodos para reduzir um ou mais efeitos colaterais da terapia de glicocorticóide, e para tratar ou previnir um padrão de secreção de glicocorticóide endógeno diminuído ou interrompido em um paciente. | |
BRPI1014824A2 (pt) | composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo | |
BRPI0920847A2 (pt) | composto, formulação farmacêutica, e, método para o tratamento, prevenção ou retardo na progressão de câncer em um paciente | |
EP2273982A4 (en) | DELAYED FORMS HAVING DIFFERENT RELEASING PROFILES TO MITIGATE, PREVENT OR TREAT PAIN OR INFLAMMATION | |
BR112014003997A2 (pt) | composto, método para inibição da atividade de pak1 em uma célula e paciente, método para o tratamento ou melhoria da gravidade do câncer ou de um distúrbio hiperproliferativo em um paciente, utilização do composto e composição | |
BRPI0811845A2 (pt) | Forma de dosagem, e, métodos de preparação da forma de dosagem, e de tratamento de uma má condição em um paciente | |
WO2012091956A3 (en) | Continuous indentation lateral lobe apparatus and method | |
NI201200090A (es) | Composiciones para tratar náusea y vómito centralmente mediados | |
EP2600937B8 (en) | Systems for treating acute and/or chronic injuries in soft tissue | |
BR112012008854A2 (pt) | combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
EP2532680A4 (en) | MEDICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
IL225632A0 (en) | Preparations containing a topical base and an active substance, and methods for further improvement and treatment | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
WO2008122049A3 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BRPI0814776A2 (pt) | Método para manter consistência para tratamentos de distribuição de droga em aerossol, e, aparelho para distribuição de droga em aerossol | |
BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
BRPI1013957A2 (pt) | método para produzir exossomas moduladores imunes específicos, composição farmacêutica, exossoma, e, método para tratar um indivíduo em necessidade do tratamento. | |
BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
WO2008137867A3 (en) | Compositions comprising mir34 therapeutic agents for treating cancer | |
BRPI0915986A2 (pt) | composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo | |
HK1162366A1 (en) | Devices and methods for treating and or preventing diseases | |
EP2165715A4 (en) | THERAPEUTIC AGENT FOR CANCER AND METHOD FOR TREATING CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |